Serum leptin in obese patients with Laron syndrome before and during IGF-I treatment.
Fifteen patients with primary GH resistance (Laron syndrome, LS) were studied before and during 6 months of daily replacement treatment with IGF-I. The main findings were that patients with LS and normal or high serum GH binding protein (GHBP) were less obese than those with a negative GHBP, and that serum leptin levels varied with body mass as in other types of obesity.
Laron
Z
Z
Endocrine & Diabetes Research Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Silbergeld
A
A
Lilos
P
P
Blum
F W
FW
D000328:Adult; D001823:Body Composition; D002352:Carrier Proteins / Q000097:blood; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D005260:Female; D019382:Human Growth Hormone; D006801:Humans; D007223:Infant; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000172:deficiency / Q000627:therapeutic use*; D020738:Leptin; D008297:Male; D009154:Mutation; D009765:Obesity / Q000097:blood* / Q000188:drug therapy / Q000235:genetics*; D011506:Proteins / Q000032:analysis*; D054411:Receptors, Leptin; D011986:Receptors, Somatotropin / Q000235:genetics*
D002352:Carrier Proteins; D007328:Insulin; C515448:LEPR protein, human; D020738:Leptin; D011506:Proteins; D054411:Receptors, Leptin; D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; C051815:somatotropin-binding protein